Imatinib inhibited BCR-ABL kinase activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.